MOLN - Will Novartis Q4 results bring positive surprise amid buzz surrounding Sandoz?
Novartis (NYSE:NVS) is scheduled to announce Q4 earnings results on Wednesday, February 2nd, before market open. The consensus EPS Estimate is $1.44 (+7.5% Y/Y) and the consensus Revenue Estimate is $13.28B (+4.0% Y/Y). Over the last 2 years, NVS has beaten EPS estimates 75% of the time and has beaten revenue estimates 50% of the time. Over the last 3 months, EPS estimates have seen 0 upward revisions and 1 downward. Revenue estimates have seen 1 upward revision and 5 downward. The company's stock rose +1.77% on Oct. 26, the day it reported its Q3 results. The company met analyst expectations for quarterly revenue despite recording better-than-expected non-GAAP earnings for Q3. Business Highlights: On Feb. 1 it was reported that private equity firms Blackstone (NYSE:BX) and Carlyle Group (NASDAQ:CG) are said to be in discussions to possibly team up to bid for Novartis' Sandoz generics unit. Novartis still hasn't decided if it will spin
For further details see:
Will Novartis Q4 results bring positive surprise amid buzz surrounding Sandoz?